Observational studyBMC endocrine disorders2026
Clinical significance of coexisting Hashimoto's thyroiditis in differentiated thyroid cancer: a retrospective cohort study.
Observational study in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe association between Hashimoto's Thyroiditis (HT) and the clinicopathological behavior of Differentiated Thyroid Cancer (DTC) remains controversial. In particular, whether coexisting autoimmune thyroiditis independently influences invasive tumor characteristics after adjustment for tumor-related factors remains unclear. This study aimed to evaluate the relationship between HT and clinicopathological features of DTC, with a focus on tumor size, lymph node metastasis, and pathological indicators of tumor aggressiveness.
methodsThis retrospective observational study included 198 patients with histologically confirmed DTC who underwent thyroidectomy between June 2023 and March 2025. Patients were stratified according to the presence or absence of Hashimoto's Thyroiditis. Tumor size, lymph node metastasis, capsular invasion, and extrathyroidal extension were compared between groups. Tumor aggressiveness was defined as capsular invasion and/or extrathyroidal extension. Multivariate logistic regression analysis was performed to assess independent associations. Model performance was evaluated using receiver operating characteristic (ROC) analysis and nomogram visualization.
resultsPatients with coexisting HT presented with significantly smaller tumors compared with those without HT (median tumor size: 9 mm vs. 12 mm; p = 0.003). Lymph node metastasis was observed less frequently in the HT group than in the non-HT group (4.1% vs. 46.8%; p < 0.001). In multivariate analysis, tumor size was independently associated with tumor aggressiveness (odds ratio [OR] = 1.49, 95% confidence interval [CI]: 1.11-1.99; p = 0.008), whereas HT was not independently associated with aggressive pathological features (OR = 1.10, 95% CI: 0.70-1.73; p = 0.692). The predictive model demonstrated limited discriminative ability (AUC = 0.587), although calibration was acceptable.
conclusionsHashimoto's Thyroiditis is associated with smaller tumor size and a lower prevalence of lymph node metastasis in patients with Differentiated Thyroid Cancer. However, HT is not an independent predictor of pathological tumor aggressiveness after adjustment for tumor size. These findings suggest that HT may influence disease presentation but should not be considered a standalone prognostic factor for invasive tumor behavior.
trial registrationNot applicable. This study was a retrospective observational cohort study and did not involve prospective clinical trial registration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.